What looks like “moving fast” in early-stage companies is often disguised misalignment — and fixing it early is what allows teams to actually accelerate later.
Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone.